Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dianthus Therapeutics, Inc. (Nasdaq: DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing ...